Assessment and Monitoring Challenges Among Patients With Moderate-to-Severe Atopic Dermatitis Across Fitzpatrick Skin Types: A Photographic Review and Case Series.
Valéria Aoki(Universidade de São Paulo), Eric L. Simpson(Oregon Health & Science University), Colleen Wegzyn(AbbVie (United States)), Barry Ladizinski(AbbVie (United States)), Susan Jewell(Netherlands Institute for Radio Astronomy), Seemal R. Desai(The University of Texas Southwestern Medical Center)
Cited by 5
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
|British Journal of Dermatology|2020|590
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults
|Journal of the American Academy of Dermatology|2016|564
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
|JAMA Dermatology|2019|505